Kura Oncology, Inc. $KURA Shares Purchased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. boosted its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 23.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 47,013 shares of the company’s stock after buying an additional 9,069 shares during the quarter. Harbor Capital Advisors Inc. owned 0.05% of Kura Oncology worth $271,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Kura Oncology during the 1st quarter worth approximately $139,000. Jacobs Levy Equity Management Inc. lifted its holdings in Kura Oncology by 57.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,544,113 shares of the company’s stock worth $10,191,000 after buying an additional 566,193 shares in the last quarter. Rhumbline Advisers lifted its holdings in Kura Oncology by 5.2% during the 1st quarter. Rhumbline Advisers now owns 105,206 shares of the company’s stock worth $694,000 after buying an additional 5,215 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in Kura Oncology by 26.5% during the 1st quarter. Hsbc Holdings PLC now owns 54,491 shares of the company’s stock worth $351,000 after buying an additional 11,406 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Kura Oncology by 7.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock worth $1,147,000 after buying an additional 9,050 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 26th. Wall Street Zen upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. Guggenheim started coverage on shares of Kura Oncology in a report on Thursday, September 4th. They issued a “neutral” rating on the stock. JMP Securities reduced their price objective on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating on the stock in a report on Monday, August 11th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.10.

Insider Buying and Selling

In related news, CEO Troy Edward Wilson acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The shares were purchased at an average price of $8.20 per share, with a total value of $410,000.00. Following the completion of the acquisition, the chief executive officer owned 100,968 shares in the company, valued at approximately $827,937.60. This represents a 98.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.40% of the company’s stock.

Kura Oncology Stock Down 2.3%

Shares of NASDAQ:KURA opened at $8.25 on Friday. The company has a market cap of $716.10 million, a price-to-earnings ratio of -3.65 and a beta of 0.19. The firm’s 50-day simple moving average is $7.13 and its 200-day simple moving average is $6.61. The company has a quick ratio of 6.16, a current ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.40.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to analyst estimates of $64.95 million. As a group, equities research analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.